TG1024

DB06180ExperimentalGene Therapies

Investigated for use/treatment in solid tumors and melanoma.

Primary indication
Investigated for use/treatment in solid tumors and melanoma.Curator reviewed
Also known as
Ad-IL2
Code names
TG-1024

Which companies are running trials of TG1024, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In